Interest and Impact of Skin Cancer Genetic Testing

Non-melanoma Skin Cancer (NMSC) Clinical Trial

Official title:

PERSONALIZED GENOMIC TESTING FOR MELANOMA: MAXIMIZING COMPREHENSION AND HEALTH OUTCOMES IN SKIN CANCER PATIENTS

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02941900
• Other study ID #: 16-1243
• Status: Completed
• Start date: August 2016
• Est. completion date: January 18, 2023

Study information

• Verified date: January 2023
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to learn whether the patient might be interested in skin cancer genetic testing, and if so, what kinds of thoughts, feelings, and behaviors might result from this testing. Testing for skin cancer risk based on the MC1R gene is not currently used in clinical practice; it will be offered in this study for research purposes only.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 53
• Est. completion date: January 18, 2023
• Est. primary completion date: January 18, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age or older
• English fluent as we do not have the resources to translate all the materials including the website and risk feedback materials into other languages
• Prior history of stage 0, I or II NMSC as per EMR or clinical judgment

Exclusion Criteria:

• Inability to provide meaningful informed consent due to cognitive or psychiatric disability as determined by the judgement of the consenting professional or clinician

Related Conditions & MeSH terms

• Non-melanoma Skin Cancer (NMSC)
• Skin Neoplasms

Intervention

Genetic:
• MC1R genotyping

Behavioral:
• MC1R Testing Website
The website includes three educational modules about genetic testing with corresponding knowledge questions.
• Baseline Survey

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of patients interested in MC1R testing		1 year

External Links

•   Memorial Sloan Kettering Cancer Center